Chris Bakal

I am a Professor at the Institute of Cancer Research (ICR) and a founder of multiple biotech ventures translating frontier science into impact. As CEO of Sentinal4D, I lead the development of AI and imaging technologies that predict therapy resistance and guide precision oncology. As CSO of Eidolon, I’m developing novel effector-based therapeutics and oncolytic viruses to transform immunotherapy. Through Hibakari Dynamics, my venture studio, I incubate high-risk, high-reward Bio-AI companies in aging, biodefense, inflammation, and beyond.

My work bridges academic leadership and company building, with a vision to create a new generation of biotech founded on AI, cell dynamics, and pathogen biology.